This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Future Prospects Of Global Personalized Medicine Market 2012-2016

NEW YORK, July 23, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Future Prospects of Global Personalized Medicine Market 2012-2016                                    http://www.reportlinker.com/p01556751/Future-Prospects-of-Global-Personalized-Medicine-Market-2012-2016.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

TechNavio's analysts forecast the Global Personalized Medicine market 2012-2016 to grow at a CAGR of 12.07 percent over the period 2012-2016. One of the key factors contributing to this market growth is the significant growth of the Targeted Biologics segment. The Global Personalized Medicine market has also been witnessing an increase in the number of mergers ad acquisitions. However, the low awareness of personalized medicine in developing countries could pose a challenge to the growth of this market. TechNavio's report, the Future Prospects of Global Personalized Medicine Market 2012-2016, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market in the Americas, and the EMEA and APAC regions; it also covers the Global Personalized Medicine market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.The key vendors dominating this space include Abbott Laboratories, AstraZeneca plc, F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc., and Sanofi S.A.The other vendors mentioned in the report are Affymetrix Inc., Agendia B.V., Agilent Technologies Inc., Amgen Inc., Astellas Pharma Inc., Baxter International Inc., Bayer AG, BG Medicine Inc., Biocartis S.A, Biogen Idec Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Co., Celgene Corp., Daiichi Sankyo Co. Ltd., Danaher Corp., Eli Lilly and Co., Evotec AG, GE Healthcare Ltd., Genelex Corp., GlaxoSmithKline plc, Hologic Inc., Johnson & Johnson, Laboratory Corporation of America Holdings, Life Technologies Corp., Merck KGaA, Mitsubishi Tanabe Pharma Corp., Myriad Genetics Inc., Novartis AG, PerkinElmer Inc., Pfizer Inc., Quest Diagnostics Inc., Sanofi S.A., Siemens Healthcare, Sigma-Aldrich Corp., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Thermo Fisher Scientific Inc., and Transgenomic Inc.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,117.51 +93.45 0.52%
S&P 500 2,119.44 +11.15 0.53%
NASDAQ 5,038.0210 +32.63 0.65%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs